南华生物
(000504)
| 流通市值：40.88亿 | | | 总市值：40.99亿 |
| 流通股本：3.29亿 | | | 总股本：3.30亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 295,914,290.97 | 119,301,354.8 | 415,939,732.49 | 83,438,454.98 |
| 营业收入 | 295,914,290.97 | 119,301,354.8 | 415,939,732.49 | 83,438,454.98 |
| 二、营业总成本 | 299,810,787.12 | 109,875,018.81 | 403,227,245.62 | 87,427,614.24 |
| 营业成本 | 266,294,567.93 | 94,889,574.69 | 324,142,778.16 | 30,517,389.18 |
| 税金及附加 | 2,565,962.09 | 1,207,550.4 | 3,313,504.18 | 592,177.9 |
| 销售费用 | 6,689,700.83 | 3,318,918.24 | 22,130,617.15 | 17,251,814.22 |
| 管理费用 | 14,712,517.16 | 5,952,343.03 | 44,274,472.42 | 33,025,413.87 |
| 研发费用 | 5,534,664.84 | 2,187,521.47 | 7,662,930.35 | 6,236,518.78 |
| 财务费用 | 4,013,374.27 | 2,319,110.98 | 1,702,943.36 | -195,699.71 |
| 其中:利息费用 | 4,334,148.99 | 2,406,123.27 | 2,587,480.62 | 650,210.8 |
| 其中:利息收入 | 406,451.79 | 139,256.5 | 1,130,084.12 | 1,074,995.45 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | -165,128 | -151,263 |
| 加:投资收益 | 1,524,115.62 | 498,691.5 | 7,874,289.7 | 5,310,324.47 |
| 资产处置收益 | -713.47 | - | 4,854.13 | 32,482.62 |
| 资产减值损失(新) | - | - | -2,538,451.19 | - |
| 信用减值损失(新) | -4,120,591.21 | - | -14,286,018.6 | -4,167,695.97 |
| 其他收益 | 4,508,637.56 | 1,683,565 | 16,445,840.56 | 484,135.04 |
| 四、营业利润 | -1,985,047.65 | 11,608,592.49 | 20,047,873.47 | -2,481,176.1 |
| 加:营业外收入 | 7,230.08 | 4,691.76 | 509,972.29 | 1,594 |
| 减:营业外支出 | 66,630.23 | 65,850.31 | 835,234.22 | 631,453.58 |
| 五、利润总额 | -2,044,447.8 | 11,547,433.94 | 19,722,611.54 | -3,111,035.68 |
| 减:所得税费用 | -2,909,461.11 | 471,585.26 | 1,670,331.45 | 38,548.34 |
| 六、净利润 | 865,013.31 | 11,075,848.68 | 18,052,280.09 | -3,149,584.02 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 865,013.31 | - | 18,052,280.09 | -3,149,584.02 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 5,992,694.22 | 11,100,681.89 | 28,828,686.12 | 5,232,334.61 |
| 少数股东损益 | -5,127,680.91 | -24,833.21 | -10,776,406.03 | -8,381,918.63 |
| 扣除非经常损益后的净利润 | 4,317,039.58 | 10,337,836.54 | 10,690,296.17 | 397,675.87 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.02 | 0.03 | 0.09 | 0.02 |
| (二)稀释每股收益 | 0.02 | 0.03 | 0.09 | 0.02 |
| 九、综合收益总额 | 865,013.31 | 11,075,848.68 | 18,052,280.09 | -3,149,584.02 |
| 归属于母公司股东的综合收益总额 | 5,992,694.22 | 11,100,681.89 | 28,828,686.12 | 5,232,334.61 |
| 归属于少数股东的综合收益总额 | -5,127,680.91 | -24,833.21 | -10,776,406.03 | -8,381,918.63 |
| 公告日期 | 2026-08-24 | 2026-04-29 | 2026-04-29 | 2025-10-27 |
| 审计意见(境内) | | | 标准无保留意见 | |